Compare GeneDx Holdings Corp (WGS) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GeneDx Holdings Corp vs Xpeng Inc - ADR — how do they compare? GeneDx Holdings Corp trades at $86.53 (market cap $2.56B), while Xpeng Inc - ADR trades at $10.6 (market cap $10.34B). The key difference: Xpeng Inc - ADR is far larger — about 4× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals.
| WGS | XPEV | |
|---|---|---|
Market Cap | $2.56B | $10.34B |
Sector | Technology | Consumer Cyclical |
52-Week High | $167.51 | $28.07 |
52-Week Low | $34.51 | $10.57 |
Enterprise Value | $2.60B | $12.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
XPEV trades at $10.93, down 0.18% for the day, with a bearish technical signal from moving averages. The company reported a net loss of $1.14B in 2025 despite revenue growth to $76.72B, and recent quarterly earnings missed expectations. Positive developments include a $900M robotics unit funding at a $6.3B valuation and new model launches aimed at boosting deliveries.
The outlook remains cautious due to persistent losses and competitive pressures, but analyst consensus is bullish with a $19 price target. Key risks include execution challenges in EV and robotics segments, while institutional interest and AI-driven initiatives offer potential upside if profitability improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
